{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:47:03Z","timestamp":1789199223113,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clml.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T18:29:06Z","timestamp":1659896946000},"page":"903-911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0792-8595","authenticated-orcid":false,"given":"Jessica","family":"Caro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Madero-Marroquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zubizarreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-4709","authenticated-orcid":false,"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Coltoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Lancman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3263-166X","authenticated-orcid":false,"given":"Risa","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-886X","authenticated-orcid":false,"given":"Samantha E.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.08.001_bib0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.08.001_bib0002","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.08.001_bib0003","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B","article-title":"Fever and infection in leukemic patients: a study of 494 consecutive patients","volume":"41","author":"Bodey","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.08.001_bib0004","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/598620","article-title":"Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria","volume":"29","author":"Zinner","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","article-title":"The current spectrum of infection in cancer patients with chemotherapy related neutropenia","volume":"42","author":"Nesher","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.clml.2022.08.001_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.idh.2019.08.006","article-title":"Bloodstream infections in neutropenic patients with haematological malignancies","volume":"25","author":"Carvalho","year":"2020","journal-title":"Infect Dis Health"},{"key":"10.1016\/j.clml.2022.08.001_bib0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/374339","article-title":"Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States","volume":"36","author":"Wisplinghoff","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14740\/jh751","article-title":"Treatment-Related Mortality From Infectious Complications in an Acute Leukemia Clinic","volume":"9","author":"Torres-Flores","year":"2020","journal-title":"J Hematol"},{"key":"10.1016\/j.clml.2022.08.001_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3111\/13696998.2010.542393","article-title":"Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French health care system","volume":"14","author":"Michallet","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2022.08.001_bib0010","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.08.001_bib0011","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.08.001_bib0012","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2022.08.001_bib0013","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood.V120.21.2077.2077","article-title":"Fluoroquinolone prophylaxis following induction chemotherapy in patients with acute leukemia: patterns of infection","volume":"120","author":"Reagan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.001_bib0014","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.08.001_bib0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/dkm514","article-title":"Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution","volume":"61","author":"Cattaneo","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clml.2022.08.001_bib0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/1471-2334-13-563","article-title":"Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis","volume":"13","author":"De Rosa","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2013.07.018","article-title":"Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in patients with cancer","volume":"42","author":"Ha","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clml.2022.08.001_bib0018","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/648451","article-title":"Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"30","author":"Gasink","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clml.2022.08.001_bib0019","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/10428194.2010.518655","article-title":"Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance","volume":"52","author":"Ng","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.08.001_bib0020","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/cid\/cix644","article-title":"Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia","volume":"65","author":"Wolf","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0021","series-title":"Common terminology criteria for adverse events v5.0 (CTCAE)","year":"2017"},{"key":"10.1016\/j.clml.2022.08.001_bib0022","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2022.08.001_bib0023","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.08.001_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clml.2022.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2022.08.001_bib0026","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clml.2022.08.001_bib0027","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2022.08.001_bib0028","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1002\/sim.7059","article-title":"Prevalence odds ratio versus prevalence ratio: choice comes with consequences","volume":"35","author":"Tamhane","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2022.08.001_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.clml.2022.08.001_bib0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/1471-2334-13-356","article-title":"Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance","volume":"13","author":"Garnica","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0031","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cncr.11044","article-title":"Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli","volume":"97","author":"Gomez","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.08.001_bib0032","doi-asserted-by":"crossref","unstructured":"Ziegler M, Han JH, Landsburg D, et\u00a0al. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy. Open Forum Infectious Diseases2019; 6:ofz252. doi:10.1093\/ofid\/ofz252","DOI":"10.1093\/ofid\/ofz252"},{"key":"10.1016\/j.clml.2022.08.001_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciz777","article-title":"Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia","volume":"71","author":"Galloway-Pe\u00f1a","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0034","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.3748\/wjg.v20.i21.6602","article-title":"Hematologic diseases: high risk of Clostridium difficile associated diarrhea","volume":"20","author":"Gweon","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2022.08.001_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","article-title":"Effects of control interventions on Clostridium difficile infection in England: an observational study","volume":"17","author":"Dingle","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clml.2022.08.001_bib0036","doi-asserted-by":"crossref","first-page":"e28469","DOI":"10.1002\/pbc.28469","article-title":"Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia","volume":"67","author":"McCormick","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2022.08.001_bib0037","doi-asserted-by":"crossref","first-page":"e28643","DOI":"10.1002\/pbc.28643","article-title":"Levofloxacin prophylaxis in hospitalized children with leukemia: a cost-utility analysis","volume":"67","author":"Maser","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2022.08.001_bib0038","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.riam.2017.09.006","article-title":"Cost-effectiveness of posaconazole in private and public Brazilian hospitals","volume":"35","author":"Tuon","year":"2018","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.clml.2022.08.001_bib0039","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.bbmt.2018.11.023","article-title":"Fluoroquinolone prophylaxis is highly effective for the prevention of central line-associated bloodstream infections in autologous stem cell transplant patients","volume":"25","author":"Ziegler","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.08.001_bib0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/23744235.2016.1143963","article-title":"Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: A single-centre study","volume":"48","author":"Hallb\u00f6\u00f6k","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.clml.2022.08.001_bib0041","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant enterobacterales decreases the e of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:07Z","timestamp":1761871267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2152265022002385"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.08.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}